Please ensure Javascript is enabled for purposes of website accessibility

3 Ways Big Pharma Is Seizing This Rare Opportunity

By Keith Speights - Apr 4, 2013 at 6:36PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Big pharma eyes big profits by targeting rare diseases. Here's how they're moving forward.

Making money in business typically happens in one of two ways. You either sell a relatively low-cost product to a large number of customers. The other option is to sell a high-cost product to a small number of customers.

After years of going with the former approach, big pharma knows that to succeed in the future requires more of the latter. That's why several major pharmaceutical companies have been building up their capabilities to tackle the red-hot market for drugs that treat orphan diseases affecting small numbers of patients. Here are three ways that the large drugmakers are seizing this "rare" opportunity.

1. The old-fashioned way
Several companies started from scratch by researching and developing drugs for orphan diseases. Eli Lilly (LLY 4.39%) actually began this process years ago. The company received approval from the Food and Drug Administration for Alimta in 2004. Alimta became the first drug approved in the U.S. for treating malignant pleural mesothelioma, a rare form of cancer with only around 2,000 new diagnoses each year.Lilly has experienced tremendous success with Alimta, which generated nearly $2.6 billion in sales last year

Sometimes drugs that originally focus on more common diseases can also help address orphan diseases. Lilly's tabalumab, for example, is farthest along in development as a treatment for lupus. A phase 3 clinical study is currently under way with the drug targeting this disease. However, tabalumab was also designated by the FDA late last year as an orphan drug for treating multiple myeloma and is in a phase 2 trial for the more rare indication.

2. Making a big deal
Another approach for big pharmaceutical firms seeking to profit from the orphan drug market is to strike a big deal with a company that has products already far along in the pipeline. Merck (MRK 1.58%) took this path a year ago when it forged a partnership with Endocyte (NASDAQ: ECYT). The big pharmaceutical company paid $120 million upfront and could pay up to $880 million more if certain milestones are met with Endocyte's star product, vintafolide.

Vintafolide received orphan drug status in March 2012 in Europe. The drug is currently in a phase 3 clinical trial targeting platinum-resistant ovarian cancer and is in a phase 2 trial focusing on non-small-cell lung cancer. 

Merck's possible $1 billion payout could prove to be a good investment if Wedbush analyst Gregory Wade is right. Wade estimates that vintafolide could hit peak sales in Europe of $400 million per year if approved later this year. He thinks another $500 million could be added to that annual total if the drug also receives approval in the U.S.

3. Thinking small
While Merck struck a big deal with Endocyte, smaller arrangements are more common. Pfizer (PFE 3.59%), for example, licensed small biotech Repligen's spinal muscular atrophy program earlier this year. Under the terms of the agreement, Pfizer paid $5 million upfront with potential future milestone payments up to $65 million. Repligen's RG3039 drug has received orphan designations in both the U.S. and Europe.

Pfizer took the "thinking small" approach back in 2009 also. The big drugmaker inked a deal then with Protalix BioTherapeutics for rights to Gaucher disease drug Elelyso for $60 million upfront and up to $55 million in milestone payments. Pfizer and Protalix gained FDA approval for the drug in May 2012. 

Just a few weeks ago, AbbVie (ABBV -0.47%) threw a twist into this approach. Rather than buy rights for an orphan drug from a small biotech, the big pharma did the opposite. In March, small biotech Receptos licensed an experimental drug targeting orphan disease eosinophilic esophagitis from AbbVie. 

Rare opportunity
Big pharma companies appear likely to continue scaling up investments in drugs targeting orphan diseases. This hopefully will translate to better care for patients suffering from these rare diseases. Shareholders of the large pharmaceutical companies should profit from this focus. Investors in smaller biotechs that attract the interest of these bigger companies benefit also. The orphan drug market presents a win/win/win proposition. That's rare.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$52.47 (3.59%) $1.82
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$93.55 (1.58%) $1.46
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$298.85 (4.39%) $12.58
AbbVie Inc. Stock Quote
AbbVie Inc.
$151.01 (-0.47%) $0.71

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.